Eli Lilly recently launched an exciting new version of its popular obesity drug, Zepbound. This new version comes in a convenient KwikPen that provides a month’s worth of doses in one handy device. Patients can buy this multi-dose pen directly from Lilly’s website, starting at $299 for the lowest dose.
This innovation simplifies the process for patients. Instead of using a different single-dose device every week, they can now use just one pen for four weekly doses. Previously, they had to draw the medication from vials or use individual autoinjectors, which could be more cumbersome.
Zepbound has seen a surge in popularity since its launch late last year, helping Eli Lilly capture a large portion of the weight-loss drug market away from competitors like Novo Nordisk. In the last quarter alone, Zepbound generated $4.2 billion in U.S. revenue—a remarkable increase of 122% from the previous year.
The FDA has also approved this new KwikPen, which is already popular for other Lilly drugs, including Mounjaro, a diabetes medication. Ilya Yuffa, president of Lilly USA, emphasized the company’s commitment to helping people manage obesity by introducing this user-friendly option.
As health experts note, weight management is essential in today’s world, where obesity rates have climbed in recent years. According to the CDC, the prevalence of adult obesity was 41.9% in 2017-2020, a significant rise compared to previous decades. Innovations like Zepbound and its KwikPen format are crucial in supporting patients on their weight loss journeys.
In summary, Eli Lilly’s launch of Zepbound in the KwikPen format reflects a growing trend towards convenience in healthcare. As more patients seek effective solutions for weight management, such advancements can transform their experience and outcomes. For more details on the impact of obesity treatments, you can visit the CDC’s obesity page.
Source link
Business,Biotech and Pharmaceuticals,Health care industry,Eli Lilly and Co,iShares U.S. Pharmaceuticals ETF,iShares U.S. Healthcare ETF,Novo Nordisk A/S,Hims & Hers Health Inc,CVS Health Corp,business news
